The Food and Drug Administration (FDA) has approved changes to the safety label of the type 2 diabetes drug Farxiga to include stronger warnings for the risk of acute kidney injury. The update replaces the previous warning for impaired renal function. The warning states that Farxiga causes intravascular volume contradiction, which can lead to renal impairment. The FDA and the drug companies have received post-marketing reports of acute kidney injury, some requiring hospitalization and dialysis, in patients taking Farxiga. Some of the reports involved patients younger than 65. “Before initiating Farxiga, consider factors that may predispose patients to acute kidney ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.